Synapse loss is the underlying driver of disease progression in Alzheimer’s disease. The Allyx Therapeutics team discovered the underlying cellular and molecular mechanism of synapse loss, which has now been widely validated around the globe.

Amyloid-β oligomers are synaptotoxic and trigger synapse dysfunction and loss through specific receptors located on the synapse. This mechanism has been widely implicated in other neurodegenerative diseases also characterized by misfolded protein aggregates including Parkinson’s disease and infectious prion diseases.

Allyx is advancing ALX-001 an orally bioavailable drug demonstrating reversal of learning and memory deficits in multiple animal models of Alzheimer’s disease. Disease reversal was achieved by preserving and restoring damaged synapses.